SCHEMBL2836845

SCHEMBL2836845

CC(C)(C)OC(=O)NC(C(=O)c1ccc(OCC(F)(F)F)cc1)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR3 Q99500 3/20 0.47
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
MAPT P10636 1/20 0.45
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
MDM2 Q00987 2/20 0.41
PRCP P42785 2/20 0.40
GABRB1 P18505 1/20 0.38
GABRB2 P47870 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CTSS P25774 1/20 0.38
CTSK P43235 1/20 0.38
AAK1 Q2M2I8 1/20 0.37
CACNA1G O43497 1/20 0.37
CACNA1H O95180 1/20 0.37
CNR2 P34972 1/20 0.37
KCNH2 Q12809 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2833252 0.90 S1PR3 (0.46) S1PR3MEN1KMT2AMAPTHTT
SCHEMBL2834042 0.87 S1PR3 (0.48) S1PR3MAPTHTTNPSR1MDM2
SCHEMBL2835032 0.85 S1PR3 (0.46) S1PR3MDM2GABRB1GABRB2CTSS
SCHEMBL2838253 0.84 S1PR3 (0.46) S1PR3MDM2CNR2
SCHEMBL2835001 0.83 S1PR3 (0.48) S1PR3HTTMDM2GABRB1GABRB2
SCHEMBL2832303 0.82 S1PR3 (0.49) S1PR3MEN1KMT2AMDM2GABRB1
SCHEMBL2835057 0.82 S1PR3 (0.48) S1PR3HTTMDM2GABRB1GABRB2
SCHEMBL2833208 0.82 S1PR3 (0.45) S1PR3MAPTHTTMDM2GABRB1
SCHEMBL2833750 0.82 S1PR3 (0.48) S1PR3HTTMDM2NPC1RAB9A
SCHEMBL2836642 0.82 S1PR3 (0.48) S1PR3MEN1KMT2AHTTMDM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367838-B2 Amines or amino alcohols as GLYT1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2013-02-05 US disclosed
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS KOLCZEWSKI SABINE (DE) 2012-09-13 US disclosed
EP-2398558-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-12-28 EP disclosed
WO-2010094659-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS HOFFMANN-LA ROCHE, INC. 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885MEN1 2588/4885KMT2A 397/4885
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885MEN1 2588/4885KMT2A 397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.